Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. [electronic resource]
Producer: 20120427Description: 746-55 p. digitalISSN:- 1096-9896
- 3' Untranslated Regions
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Calcium-Binding Proteins -- genetics
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Cell Cycle Proteins -- genetics
- Cell Line, Tumor
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Down-Regulation
- Drug Resistance, Neoplasm -- genetics
- Female
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Mad2 Proteins
- MicroRNAs -- metabolism
- Multivariate Analysis
- Neoplasm Grading
- Neoplasm Staging
- Neoplasms, Cystic, Mucinous, and Serous -- genetics
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Paraffin Embedding
- Proportional Hazards Models
- RNA Interference
- Repressor Proteins -- genetics
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Time Factors
- Transfection
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.